Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes

Diabetes, Obesity and Metabolism

Volumn 13, Issue 9, 2011, Pages 791-799

  Mayer, P ^a   Haas, B ^a,b   Celner, J ^a,b   Enzmann, H ^a   Pfeifer, A ^b  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Adipocytes; Diabetes mellitus; Drug mechanism; Glitazones; Sulphonylureas

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; ACETYL COENZYME A CARBOXYLASE BETA; ACYL COA THIOESTERASE 2; CHEMOKINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; DIAZOXIDE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FAT DROPLET; FATTY ACID BINDING PROTEIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INSULIN; MACROPHAGE DERIVED CHEMOKINE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PYRUVATE DEHYDROGENASE KINASE 4; REPAGLINIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; MARKER GENE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROADIPOCYTE; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; WESTERN BLOTTING;

EID: 79960786696     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01409.x     Document Type: Article

References (32)

1. Funaki M. Saturated fatty acids and insulin resistance. J Med Invest 2009; 56: 88-92.
2. Oakes ND, Thalén PG, Jacinto SM, Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 2001; 50: 1158-1165.
3. Ye JM, Dzamko N, Cleasby ME et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 2004; 47: 1306-1313.
4. Tafuri SR. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology 1996; 137: 4706-4712.
5. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001; 56: 239-263.
6. White UA, Stephens JM. Transcriptional factors that promote formation of white adipose tissue. Mol Cell Endocrinol 2010; 318: 10-14.
7. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000; 16: 145-171.
8. Way JM, Harrington WW, Brown KK et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001; 142: 1269-1277.
9. Inukai K, Watanabe M, Nakashima Y et al. Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2005; 328: 484-490.
10. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 2005; 280: 23653-23659.
11. Kanda Y, Matsuda M, Tawaramoto K et al. Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone. Diabetes Res Clin Pract 2008; 81: 13-18.
12. Mori RC, Hirabara SM, Hirata AE, Okamoto MM, Machado UF. Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin. Diabetes Obes Metab 2008; 10: 596-600.
13. Nakano N, Miyazawa N, Sakurai T et al. Gliclazide inhibits proliferation but stimulates differentiation of white and brown adipocytes. J Biochem. 2007; 142: 639-645.
14. Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116: 115-124.
15. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006; 116: 33-35.
16. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-184.
17. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008; 14: 1225-1230.
18. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
19. Rajala MW, Scherer PE. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765-3773.
20. Bruun JM, Roeske-Nielsen A, Richelsen B, Fredman P, Buschard K. Sulfatide increases adiponectin and decreases TNF-alpha, IL-6, and IL-8 in human adipose tissue in vitro. Mol Cell Endocrinol 2007; 263: 142-148.
21. Hauner H, Entenmann G, Wabitsch M et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 1989; 84: 1663-1670.
22. Zilberfarb V, Piétri-Rouxel F, Jockers R et al. Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis. J Cell Sci 1997; 110: 801-807.
23. Haas B, Mayer P, Jennissen K et al. Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesis. Sci Signal 2009; 2: ra78.
24. Mayer P, Ammon S, Braun H et al. Gene expression profile after intense second messenger activation in cortical primary neurons. J Neurochem 2002; 82: 1077-1086.
25. Lee G, Elwood F, McNally J et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 2002; 277: 19649-19657.
26. Grimmsmann T, Rustenbeck I. Direct effects of diazoxide on mitochondria in pancreatic B-cells and on isolated liver mitochondria. Br J Pharmacol 1998; 123: 781-788.
27. Akar F, Uydeş-Doǧan BS, Buharalioǧlu CK et al. Protective effect of cromakalim and diazoxide, and proulcerogenic effect of glibenclamide on indomethacin-induced gastric injury. Eur J Pharmacol 1999; 374: 461-470.
28. Thummel KE, Shen DD, Isoherranen N, Smith HE. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton LL, Lazo JS, Parker KL eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e. Available from URL:.
29. Green S. Peroxisome proliferators: a model for receptor mediated carcinogenesis. Cancer Surv 1992; 14: 221-232.
30. Green S, Tugwood JD, Issemann I. The molecular mechanism of peroxisome proliferator action: a model for species differences and mechanistic risk assessment. Toxicol Lett 1992; 64-65: 131-139.
31. Di Gregorio GB, Yao-Borengasser A, Rasouli N et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005; 54: 2305-2313.
32. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003; 100: 7265-7270.